Background: The relationship between tuberculosis (TB) and subsequent chronic kidney disease (CKD) remains unclear. Therefore, we examined the risk of CKD among patients with TB in a nationwide study. Methods: We conducted a retrospective cohort study using data from the National Health Insurance system of Taiwan. The cohort included 8735 patients who were newly diagnosed with TB. Patients were recruited between 1998 and 2002, and the date of diagnosis was defined as the index date. Each patient was randomly matched with four people from the general population without TB, according to age, gender and the index year. The occurrence of CKD was followed up until the end of 2011. The relative risks of CKD were estimated using the Cox proportional hazard model after
Introduction
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, which can affect multiple organs. It remains the most prevalent infectious disease and major leading cause of death worldwide. Every year, about 9 million people develop this disease and 1.4 million die of it, over 95% of them are from developing countries. 1 TB is endemic in Taiwan; more than 10 000 new TB cases are diagnosed every year. The annual incidence is $62-75 per 100 000 people. 2 TB is associated with several factors, including age, 3 sex, 4 malnutrition, 5 diabetes mellitus, 6 organ transplantation, 7-9 malignancy, 10 human immunodeficiency virus (HIV) infection 11 and chronic renal disease. 12 Chronic kidney disease (CKD) is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific and might include feeling generally unwell and experiencing a reduced appetite. It is differentiated from acute kidney injury (AKI) in that the reduction in kidney function must be present for over 3 months. Taiwan is reported to have the highest incidence and prevalence of CKD worldwide; the overall prevalence of end stage renal disease (ESRD) is 6.9% for CKD stages 3-5 and 11.9% for CKD stages 1-5. 13 The four most common causes of CKD in Taiwan are diabetes mellitus, chronic glomerulonephritis, hypertension and chronic interstitial nephritis. 13 CKD patients have higher risks of developing TB than the general population, a result of CKD itself or treatment-related immunosuppression. Li et al.
14 conducted a 9-year longitudinal cohort study and found that the risk of TB is 4.5 times greater in ESRD patients than the general population. However, TB is considered to be a chronic infectious disease and the causality between TB and CKD remained unknown. There is also some evidence that TB may result in CKD and ESRD in several case reports. [15] [16] [17] Furthermore, several chemotherapeutic agents that are used for TB treatment, including rifampin, isoniazid and ethambutol, have nephrotoxicity. 18 Therefore, we attempted to determine if there is an increased risk of CKD in patients with TB by conducting a nationwide, population-based retrospective cohort study in Taiwan with data obtained from the National Health Insurance Research Database (NHIRD).
Materials and Methods

Data source
The Taiwan Department of Health launched the social insurance system, the NHI program, which requires only minimal copayment fees and covers more than 99% of Taiwanese (23.74 million). We used the Longitudinal Health Insurance Database (LHID), established by the National Health Research Institutes (NHRI), Ministry of Health and Welfare, Taiwan, for this study. The LHID database includes claims data from 1996 to 2011 for 1 million people covered in the Taiwan NHI program.
The LHID database has information on basic patient demographics and medical care received, including outpatient and inpatient claims. The International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes are accurate and a valid tool for identifying patients with specific diseases. Personal identification information was encrypted before the release of the research database to protect patient privacy and data security. This study was censored by the institutional review board of China Medical University (CMU-REC-101-012).
Study design and study participants
This study is a retrospective, population-based cohort study. We identified 8735 subjects with TB (ICD-9-CM code 010-018) from 1998 to 2002 as the TB cohort and the date of diagnosis as the index date. Four control subjects were randomly selected for each TB case, frequency-matched for age, sex and index year using a non-TB cohort (n = 34 940). The risk of developing CKD (ICD-9-CM 585) was calculated in both cohorts. Subjects in both cohorts with a history of any kidney disease (ICD-9-CM 580-589) before the index date were excluded from this study. The urbanization level of where the study subjects resided were also included in this study. There are seven levels of urbanization in Taiwan, divided on the basis of the Taiwan National Health Research Institutes report, with the most urbanized area as level 1. Because the number of subjects is too small in levels 6 and 7, we combined urbanization levels 5-7 into level 5. All the study subjects were followed from the index date until the diagnosis of CKD, withdrawal from the LHID database or 31 December 2011. Subjects with history of hypertension (ICD-9-CM 401-405), diabetes (ICD-9-CM 250) and/or hyperlipidemia (ICD-9-CM 272) were identified before the index date to deal with the potential confounding risk factor of CKD.
Statistical analysis
To compare the differences of demographic status and proportion of comorbidity between the TB cohort and non-TB cohort, Student's t-test for continuous variables and chi-square test for categorical variables was used. The incidence rate of CKD was calculated by using the number of CKD incidents divided by the number of people (per 1000 person-years) at risk in both cohorts. We used the Cox proportional hazards model to evaluate the crude hazard ratios (HRs) and the 95% confidence interval (CI) of CKD in the TB and non-TB cohorts for various variables. After controlling for potential confounding risk factors including sex, age, urbanization and comorbidities, we calculated the adjusted HR and 95% CI of CKD in both cohorts by the multivariable Cox proportional hazards model. We also used the Cox model to estimate the HR of CKD associated with comorbidity, compared with the non-TB cohort.
All statistical analyses used SAS 9.3 statistical package (SAS Institute Inc., NC), with P value < 0.05 in two-tailed tests considered significant. We also utilized Statistical Product and Service Solutions, IBM, Chicago (SPSS statistics [version 18 .0]), to conduct a Kaplan-Meier analysis to measure the cumulative CKD incidence for TB and comparison cohorts and used the log-rank test to estimate the differences between the two cumulative incidence curves.
Results
We analyzed 8735 patients in the TB cohort and 34 940 participants in the non-TB cohort (Table 1) . After frequency matching, the TB and non-TB cohorts had similar distributions of sex and age; a majority of the subjects enrolled in this study were male (59.4%) and over 50-years-old of age (51.6%). We calculated the mean age standard deviation by Student's t test; 50.3 21.5 years for the TB cohort and 50.1 21.4 years for the non-TB cohort. In both cohorts, over 50% of subjects lived in an urbanization level of 1 and 2 (51.7% for the TB cohort and 56.3% for the non-TB cohort). Patients with TB showed higher proportions of comorbidity than the non-TB cohort, including hypertension (25.1 vs. 24.6%), hyperlipidemia (9.88 vs. 9.41%) and diabetes (9.9 vs. 6.97%) but only diabetes achieved significance. Table 2 lists the overall incidence of CKD, which was 27% higher in the TB cohort than in the non-TB cohort (3.28 vs. 2.60 per 1000 person-years). The crude HR of CKD was 1.27 (95% CI: 1.10-1.45), and adjusted HR of CKD was 1.32 (95% CI: 1.15-1.51) in the TB cohort, compared with subjects without TB. After comparing the adjusted HR of CKD in the TB cohort with the non-TB cohort by stratified analyses of sex, the adjusted HR was 1.72 (95% CI: 1.33-2.22) in females and 1.19 (95% CI: 1.01-1.41) in males. The incidence of CKD was higher in TB patients with age over 50 years, and the adjusted HR was 1.18 (95% CI: 1.01-1.37). The incidence of CKD was higher in TB patients with any comorbidity, and the adjusted HR was 1.28 (95% CI: 1.09-1.50).
We also evaluated the contribution comorbidities to the risk of CKD. The incidence of CKD was higher as the number of comorbidities increased in both cohorts (Table 3 ). In the non-TB cohort, the adjusted HR was increased with greater number of comorbidities, with an adjusted HR of 3.05 (95% CI: 2.57-3.62) with a single comorbidity, Figure 1 shows that the cumulative incidence of CKD by the end of the follow-up period was higher in the TB cohort than in the non-TB cohort (log-rank test, P = 0.002).
Discussion
To the best of our knowledge, this is the first nationwide, population-based study evaluating the relationship between TB and the subsequent risk of CKD. We identified a significant risk of CKD among TB patients compared with the general population. Further analyses showed that the adjusted HR was higher in females than males, in young than elderly and in ones without comorbidity than those with any comorbidity. In addition, we found participants with greater comorbidities had a higher incidence of developing CKD in both cohorts, and the adjusted HRs were higher in the TB cohort than in the non-TB cohort. We suggest that TB may play an independent role in the development of CKD. There is little information on the contribution that TB makes to the burden of renal disease. Data obtained from the European Dialysis and Transplant Association registry revealed 0.65% of patients had renal failure caused by TB in 1991. 19 Another data on primary renal diagnosis due to TB were 0.7% in Europe, 0.16% in Australasia and 0.004% in the Comorbidity included gypertension, hyperlipidemia and diabetes. *p < 0.05, **p < 0.01, ***p < 0.001. United States. 20 However, we should make it clear that, in our study, the CKD incidence in the TB cohort (3.48 per 1000 person-years) did not mean the causal effect was only due to TB. Furthermore, all stages of CKD in our study were enrolled not only ESRD. This is because we considered at most a 13-year follow-up period, so the effect of TB may influence renal function but may not have dramatic effects within this time period.
It is believed that 8-15% of patients with pulmonary TB develop infection in the genitourinary system via hematogenous spray. 21 Genitourinary TB was the second most common extrapulmonary TB and was a commonly missed genitourinary infection. 22 Genitourinary TB should be considered in any case of sterile pyuria, voiding symptoms, resistant urinary tract infection, obstructive nephropathy, interstitial nephritis or rarely, amyloidosis or glomerulonephritis. 23 The kidney is the most common genitourinary organ to be affected. 24 The clinical manifestations of renal TB are non-specific. In most cases, the disease results in calcification, atrophy or necrosis of the renal parenchyma. 25 Features of renal TB in imaging studies are multiple and complex. Tubercular granulomas in the renal pyramids coalesce to form ulcers. The lesions enlarge and a tubercular abscess may form in the parenchyma. Later in the course of the disease, a perinephric abscess forms and the kidney is replaced by caseous material ('putty kidney'), which may become calcified ('cement kidney') and non-functional. 26 The pathophysiology through which how TB damages the kidney and affects renal function is still not fully understood. First, a tuberculous kidney becomes calcified and gross anatomic distortion occurs. Not surprising, the glomerular filtration rate falls and usually will not recover. 27 Second, TB can induce chronic granulomatous tubulointerstitial nephritis, even if imaging shows equal-sized smooth kidneys. 16, 28 Third, TB associates with various forms of glomerulonephritis. In some situations, complications occur due to TB-related amyloidosis. 29 Shribman et al. 30 have reported a case with military TB presented with immune deposits and focal proliferative glomerulonephritis. Furthermore, any ureteral obstruction with resultant hydronephrosis can lead to irreversible changes in renal function. 17 Another concern we should always keep in mind is related to drug complications. Kidney injury is a rare and severe complication during anti-TB treatment that can cause permanent kidney damage. 31 Rifampin is the most common anti-TB drug responsible for kidney injury, although isoniazid and ethambutol have also been reported. [32] [33] [34] [35] Chang et al. 18 reported 7.1% (99/1394) patients on anti-TB treatment were identified to have AKI, 30% (30/99) of patients had comorbid CKD or ESRD and 27% (26/99) of patients did not recover from AKI in 6 months. However, this study may not provide an enough follow-up time to observe the subsequent effects of anti-TB medications.
In addition, it is common knowledge that TB patients are typically characterized by low educational attainment, low financial status, blue-collar occupations, rural dwelling, low body mass index, malnutrition, immunocompromised status and potential corticosteroid use. These attributes may be shared risk factors in both diseases and potential confounding factors that cannot be totally corrected in this study.
With respect to the validity of diagnosis, TB could be diagnosed by its typical presentation and most by bacteriological or pathological evidence. Taiwan lists TB as a type 3 notifiable disease; every newly diagnosed case has to be reported within a week to the Taiwan Centers for Disease Control. The government takes part in the treatment of every TB patient. Therefore, the data regarding TB diagnoses were reliable. [36] [37] [38] A major strength of our study is that it was performed using population-based data that are highly representative of the general population. However, certain limitations should be considered. First, the detailed stages of CKD in this study were unavailable. Second, NHIRD does not contain detailed information regarding smoking habits, diet preference, occupational exposure, drug history and family history of systemic diseases, all of which may be risk factors for TB and CKD. In addition, evidence derived from a retrospective cohort study is generally lower in statistical quality than that from a randomized trial because of potential biases associated with adjustments for confounding variables. Despite our meticulous study design and adjustment for confounding factors, biases resulting from unknown confounders may have affected our results. Last, all data in the NHIRD are anonymous. Therefore, relevant clinical variables such as serum laboratory analyses, pulmonary function tests, imaging results and pathology findings of the subjects were unavailable in our study.
Conclusion
TB patients had a significantly higher risk of developing CKD than the general population. The detailed mechanisms need further investigation. Conflict of interest: None declared.
